MicroVention | Terumo™

Terumo Website
  • Home

    • Aneurysm Therapy
    • Ischemic Stroke and Carotid Artery Disease
    • Neurovascular Malformations
    • Access Product Solutions
  • Products

    • About Us
    • Executive Team
    • News
    • Events
    • Compliance
    • Overview
    • Job Openings
  • Contact

  • Clinical Education
  • Glossary
  • MV Associates
  • Terumo Group
  • Press Resources
  • Aneurysm Therapy

    Aneurysm Therapy

  • Ischemic Stroke and Carotid Artery Disease

    Ischemic Stroke and Carotid Artery Disease

  • Neurovascular Malformation

    Neurovascular Malformations

  • Access Product Solutions

    Access Product Solutions

  • Home

News & Press

Sep 29, 2022

MicroVention Celebrates 25 Years in Neuroendovascular Technologies that Improve Patient Lives

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in a small facility in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, operating in over 70 countries with offices across the United States, Europe, Asia, and Costa Rica.

All Types
All Types Articles HR Press Releases
2022
All Years 2010 2012 2013 2015 2016 2017 2018 2019 2020 2021 2022

Sep 29, 2022

MicroVention Celebrates 25 Years in Neuroendovascular Technologies that Improve Patient Lives

MicroVention, Inc., a global neurovascular company and a wholly owned subsidiary of Terumo Corporation, celebrates its 25-year anniversary on September 29, 2022. Founded in 1997 by a handful of Associates in a small facility in Southern California, MicroVention is now a worldwide community with over 3,000 Associates and distributors worldwide, operating in over 70 countries with offices across the United States, Europe, Asia, and Costa Rica.

Sep 21, 2022

MicroVention Earns 2022 Great Place to Work Certification™

The prestigious award is based entirely on what current employees say about their experience working at MicroVention. This year, 80% of employees said it’s a great place to work – 21 points higher than the average U.S. company.

Apr 20, 2022

MicroVention Announces First Patient Enrolled in the STRAIT Study with the New BOBBY™ Balloon Guide Catheter

MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.

Feb 22, 2022

MicroVention Announces First U.S. Patient Treated with FRED™ X™ Flow Diverter Featuring X Technology

MicroVention, Inc., a subsidiary of Terumo and a global neurovascular company, announced the first U.S. clinical case of its next generation Flow Diverter, the FRED X device, at Thomas Jefferson University Hospital located in Philadelphia.

    • Aneurysm Therapy
    • Ischemic Stroke and Carotid Artery Disease
    • Neurovascular Malformations
    • Access Product Solutions
  • Products

    • About Us
    • Executive Team
    • News
    • Events
    • Compliance
    • Overview
    • Job Openings
  • Contact

  • Clinical Education
  • Glossary
  • MV Associates
  • Terumo Group
  • Press Resources
Europe, Middle East & Africa

©2023 MicroVention Inc.

Privacy Statement

For Suppliers

Terms of Use

Ordering Info Terms & Conditions

Made inHAUSHAUS is a creative design agency based in Los Angeles, California